Abstract
Introduction
In 2008, antiretroviral sales across the seven major markets totaled $10.7
billion, growing at a CAGR of 12.8% between 2005 and 2008. Datamonitor expects
this expansion to slow down. Despite drivers such as new product launches,
earlier treatment initiation, decreasing mortality and an increase in HIV
prevalence, a series of patent expiries will impact branded sales from 2011.
Key reasons to purchase this research
- Understand the changing market dynamics of HIV drugs, success factors for
leading brands and the commercial potential of late stage pipeline products
- Assess the impact of events such as patent expiries and new product
launches on individual brands and the overall antiretroviral market.
- Obtain full global, country, class and product-specific forecasts of
currently marketed and pipeline antiretrovirals from 2008 to 2018.
| 
View Cart
